SEARCH

SEARCH BY CITATION

References

  • 1
    Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 17161730.
  • 2
    Holman RR, Farmer AJ, Davies MJ et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 17361747.
  • 3
    Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881885.
  • 4
    Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193203.
  • 5
    Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 1730.
  • 6
    Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006; 32: 713.
  • 7
    Woerle HJ, Neumann C, Zschau S et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007; 77: 280285.
  • 8
    Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011; 34: 25082514.
  • 9
    Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 5866.
  • 10
    Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 4552.
  • 11
    Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008; 10: 11781185.
  • 12
    Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract 2011; 17: 727736.
  • 13
    Bergenstal RM, Johnson M, Powers MA et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008; 31: 13051310.
  • 14
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977986.
  • 15
    Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012; 28: 513523.
  • 16
    Hong ES, Khang AR, Yoon JW et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012; 14: 795802.
  • 17
    Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009; 31: 15111523.
  • 18
    Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008; 14: 285292.
  • 19
    Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012; 6: 4146.
  • 20
    Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy. J Med Econ 2011; 14: 705708.
  • 21
    Hollander P, Raslova K, Skjøth TV, Råstam J, Liutkus JF. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab 2011; 13: 268275.
  • 22
    Devries JH, Bain SC, Rodbard HW et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; 35: 14461454.
  • 23
    Wright EE Jr, Stonehouse AH, Cuddihy RM. In support of an early polypharmacy approach to the treatment of type 2 diabetes. Diabetes Obes Metab 2010; 12: 929940.
  • 24
    Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103112.
  • 25
    Zinman B. Newer insulin analogs: advances in basal insulin replacement. Diabetes Obesity Metabolism 2012; in press.
  • 26
    Hirsch IB, Bode B, Courreges JP, et al. Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care 2012; 35: 21742181.
  • 27
    Heise T, Tack CJ, Cuddihy R et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011; 34: 669674.
  • 28
    Niskanen L, Leiter LA, Franek E et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol 2012; 167: 287294.
  • 29
    Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol 2012; 6: 773779.
  • 30
    Garg SK, Kelly WC, Freson BJ, Petrucci RE, Ritchie PJ. Treat-to-target Technosphere® insulin in patients with type 1 diabetes. American Diabetes Association 71st Annual Scientific Sessions. June 24–28, 2011; San Diego, CA. Abstract 941-P.
  • 31
    Rosenstock J, Lorber DL, Gnudi L et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010; 375: 22442253.
  • 32
    Raskin P, Heller S, Honka M et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled technosphere insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab 2012; 14: 163173.
  • 33
    De Galan BE, Engwerda EE, Abbink EJ, Tack CJ. Administration of rapid-acting insulin analogs by needle-free jet injection technology advances the onset of glucose-lowering action and reduces the duration of hyperinsulinemia. American Diabetes Association 71st Annual Scientific Sessions. June 24–28, 2011; San Diego, CA. Late Breaking Abstract 28-LB.